How Do IRA Drug Pricing Policies Interact with One Another?
Stakeholders should consider the interaction of inflation-based rebates, AMP cap removal, and Medicare price negotiation in pricing and contracting strategies.
Insights on IRA Policies and Business Impacts Presented at Asembia
Avalere’s expert presentations at the AXS23 Summit described IRA drug-pricing policies and the law’s impact on patient access and affordability.
Do Drug Manufacturers Have the Evidence Needed for Price Negotiation?
Manufacturers may find significant gaps between their existing evidence and the negotiation data elements that CMS will evaluate during the negotiation process.
Operational Complexities of Providing Access to MFP for Part D Drugs
Stakeholders in the drug supply chain should consider operational complexities that will result from variable arrangements for accessing the MFP.
Demystifying IRA Drug Price Negotiation
Avalere experts will explore the potential implications of the Inflation Reduction Act (IRA)’s Medicare drug price negotiation program guidance and discuss implementation strategies for the near- and long-term.
IRA Impacts on Evidence and Strategy
Ahead of the Asembia and ISPOR 2023 conferences, Avalere experts discuss the increasing importance of value and evidence strategies as part of Inflation Reduction Act (IRA) implementation planning.
50-State Comparison of Medicaid Adult Vaccine Provider Reimbursement
A new Avalere analysis identified variability in Medicaid physician office, pharmacy, and Federally Qualified Health Centers vaccine reimbursement policies.
How Will the IRA Impact Product Launch Prices?
IRA inflation rebates and drug price negotiation will impact drug launch prices in Medicare, with spillover effects in the Medicaid and commercial markets.
IRA Impacts on Patient Access
Ahead of Asembia 2023, Avalere experts discuss how the IRA and other regulatory changes will impact patient access and affordability.
How Should Manufacturers Adjust Their Pipeline Strategies to the IRA?
In response to IRA provisions, life sciences companies should reevaluate their pipeline investment and development strategies.
What Evidence Is Needed for Medicare Drug Price Negotiation?
As CMS clarifies evidence requirements for drug price negotiations, manufacturers should prepare their strategies for asset development and on-market products.
IRA Question of the Week: How Will Negotiation Affect Reimbursement?
The introduction of the maximum fair price through the Medicare drug price negotiation process is expected to lower provider reimbursement.
Biden’s 2024 Budget: New Drug Pricing and Coverage Policies
The Biden administration’s budget outlines a healthcare policy agenda focused on drug pricing, coverage reform, infectious diseases, and biomedical research.
Medicare Drug Price Negotiation Guidance: Avalere Experts Respond
Guidance adds clarity on drug selection, maximum fair price application (MFP), evidence submission, and manufacturer engagement, but leaves questions on determining MFP.
IRA Question of the Week: How Will the Law Impact Plans and PBMs?
Part D redesign and OOP smoothing shift financial liability from beneficiaries to plans, incentivizing utilization and formulary management.
Implications of Policy Reforms on Pharmacy DIR in Part D
The use of DIR in Medicare Part D has increased in recent years, and both the IRA and CMS rulemaking are likely to influence DIR dynamics in the future.
IRA Question of the Week: How Does the Law Impact Patients?
The IRA will reduce out-of-pocket drug costs (especially in Medicare Part D), increase the availability of marketplace plans, and expand access to vaccines.
IRA Question of the Week: When Will the IRA Be Implemented?
The first Insight in this series explores timing for Medicare negotiation, inflation rebates, and Part D benefit redesign changes and details to be defined.
Evidence and Value Under the Inflation Reduction Act
In our Outlook 2023 webinar, Avalere expert Michael Ciarametaro discussed how evidence generation requirements will differ under the Inflation Reduction Act (IRA.)